Invest another $2.5 billion! Yang Sen is going to play the next big game in China.

Thirty-three years later, Yang Sen, an "old friend" of China's pharmaceutical market, is re- a big game of chess.
2.5 billion! Johnson and Johnson announced that the largest single investment in five years has officially landed in China.
This investment was completed by Xi'an Yangsen, a Chinese pharmaceutical unit owned by Johnson and Johnson, to build a new supply chain production base in Xi'an for US$397 million (RMB2.55 billion) and is scheduled to start production in the second half of 2019 as an important physical preparation production center serving China and the Asia-Pacific region as a whole.
information from Xi'an Yangsen said: 266,000 square meters of this new production base with the current advanced manufacturing technology and quality management system, the total output is expected to reach 4 billion tablets and capsules, as well as 57 million creams.
"We plan to launch seven new drugs in China over the next two years in the areas of rheumatoid arthritis, psoriasis, schizophrenia, multi-center lymph node hyperplis, HIV, diabetes and pulmonary hypertension. On the same day, Joaquin Duato, head of Johnson and Johnson's pharmaceutical business, told the media in an exclusive interview with mic366.
Johnson and Johnson's global performance boosted confidence in this important market decision.
Compared to its two other main business devices and consumer goods, the pharmaceutical business accounted for 47.4 percent of the company's total revenue in 2017, accounting for almost half of the total revenue, according to the Johnson and Johnson Group announcement data, with revenues of $36.3 billion, ranking fourth among the world's pharmaceutical companies.
new drugs began to accelerate their plans to enter China, along with the rapid opening of import approvals and innovative drug channels by the Chinese government.
In fact, information from public reports shows that since 2009, Janssen has launched 17 new products worldwide and expects to be one of the world's top 10 fastest-growing pharmaceutical companies by 2021 with more than 10 new drug registration applications and more than 50 existing drug programs expanding their product lines.in China, play chess!
, china's "oldest" multinational drugmaker, is experiencing another possibility in the country's pharmaceutical history.
2017, Johnson and Johnson committed $10.6 billion to research and development , more than most drug companies currently spend, according to public data released by the company.
high return expectations accompanied by high costs, Mr. Yang and his multinational pharmaceutical partners have caught up with the huge dividends of China's innovative drug market.
Beginning in May 2017, the State Administration of Food and Drug Administration issued a series of documents, such as the General Administration's Announcement on requesting <> (Draft for Comments) (No. 52 of 2017), with the aim of "further deepening the reform of the review and approval system, promoting the adjustment of the industrial structure and technological innovation of pharmaceutical medical devices, improving industrial competitiveness and meeting the clinical needs of the public".
Subsequently, since the release of the innovation opinions of the Central Office and the State Office in October 2017, a series of reform measures, such as the reform of innovative drug review, the management of the filing system of clinical trial institutions, the acceptance of overseas clinical trial data, and the implementation of the MAH system, have been gradually advanced;
In December of that year, Jansen announced a cooperation agreement with Legend Biotech of Nanjing to obtain permission to develop, produce, and market the latter's heavyweight CAR-T therapy, LCAR-B38M, a multiple myeloma-adaptive disease.
the two sides reached a partnership-sharing agreement - in Greater China, Yangsen and Nanjing Legend will share the cost and benefits on a 30/70 scale. In other parts of the world, the proportion is 50/50. At the start of the partnership, Jansen will pay $350 million in advance funding. With milestones such as development and regulation, Janssen will provide additional funding.
"We are taking an open partnership and innovation, working with Chinese pharmaceutical companies to find the best solutions and accelerate the launch of innovative technology research and development results, which also shows that China has changed from a major traditional pharmaceutical manufacturing country to a world pharmaceutical innovation power. In an exclusive interview, Joaquin Duato told mic366 that Jansen was looking for more different forms of cooperation between pharmaceutical companies in China.
addition, with the expansion of the list of drugs negotiated for health care negotiations year by year, multinational pharmaceutical companies, which are the absolute main players in this channel, are also experimenting with more growth opportunities.
mic366 was informed in an exclusive interview that the upcoming release of the third batch of health care negotiations drug catalog, 17 products will continue to be mainly anti-cancer drugs, of which Jansen's blood tumor treatment of the new drug Yixuan is trying to enter this channel.
past two years, we have noted that the Chinese government has issued a number of policies and measures to improve China's health care system. In particular, drugs in the field of blood tumors and other solid tumors are covered by health insurance, enabling Chinese patients to benefit from innovative therapies earlier. Asgar Rangoonwala, president of Xi'an Jansen Pharmaceuticals Co., Ltd., told Seberland. (Pharmaceutical Network)